ArriVent BioPharma, Inc. (AVBP) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
18 CAMPUS BLVD. NEWTOWN SQUARE, PA 19073-3269 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 282,855,000 | 298,669,000 | 317,393,000 | |||
| Cash and cash equivalent | 282,855,000 | 298,669,000 | 317,393,000 | |||
| Short-term investments | ||||||
| Prepaid expense | 457,000 | 745,000 | 1,035,000 | |||
| Other undisclosed current assets | 9,086,000 | 9,097,000 | 9,052,000 | |||
| Total current assets: | 292,398,000 | 308,511,000 | 327,480,000 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 187,000 | 219,000 | 250,000 | |||
| Long-term investments and receivables | ||||||
| Long-term investments | ||||||
| Other noncurrent assets | 126,000 | 125,000 | 108,000 | |||
| Total noncurrent assets: | 313,000 | 344,000 | 358,000 | |||
| TOTAL ASSETS: | 292,711,000 | 308,855,000 | 327,838,000 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 15,005,000 | 11,946,000 | 9,830,000 | |||
| Accounts payable | 4,646,000 | 3,812,000 | 4,098,000 | |||
| Accrued liabilities | 10,359,000 | 8,134,000 | 5,732,000 | |||
| Other undisclosed current liabilities | 157,000 | 152,000 | 147,000 | |||
| Total current liabilities: | 15,162,000 | 12,098,000 | 9,977,000 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 56,000 | 98,000 | 138,000 | |||
| Operating lease, liability | 56,000 | 98,000 | 138,000 | |||
| Total noncurrent liabilities: | 56,000 | 98,000 | 138,000 | |||
| Total liabilities: | 15,218,000 | 12,196,000 | 10,115,000 | |||
| Equity | ||||||
| Equity, attributable to parent | 277,493,000 | 296,659,000 | 317,723,000 | |||
| Common stock | 3,000 | 3,000 | 3,000 | |||
| Additional paid in capital | 495,190,000 | 493,792,000 | 492,982,000 | |||
| Accumulated other comprehensive loss | ||||||
| Accumulated deficit | (217,700,000) | (197,136,000) | (175,262,000) | |||
| Total equity: | 277,493,000 | 296,659,000 | 317,723,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 292,711,000 | 308,855,000 | 327,838,000 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | ||
|---|---|---|---|---|---|
| Operating expenses | (24,232,000) | (25,697,000) | (20,674,000) | ||
| Operating loss: | (24,232,000) | (25,697,000) | (20,674,000) | ||
| Nonoperating income (Investment Income, Nonoperating) | 3,668,000 | 3,823,000 | 3,257,000 | ||
| Net loss available to common stockholders, diluted: | (20,564,000) | (21,874,000) | (17,417,000) | ||
Comprehensive Income (USD)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | ||
|---|---|---|---|---|---|
| Net loss: | (20,564,000) | (21,874,000) | (17,417,000) | ||
| Other undisclosed comprehensive loss | |||||
| Comprehensive loss, net of tax, attributable to parent: | (20,564,000) | (21,874,000) | (17,417,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.